Bristol-Myers Squibb targets new approach to cancer treatment

Bristol-Myers Squibb Co is focused on becoming a next-generation biopharmaceutical company in China.

In particular, it is specializing in immuno-oncology, an innovative approach that treats cancer by teaching the patient's own immune system to identify and kill cancer cells.

There were 3.37 million new cancer cases reported in China in 2011, an increase of 280,000 compared with 2010. The five-year survival rate of cancer patients in China was about 36.9 percent last year, far lower than that in the United States and other developed countries, data from the 2015 China Cancer Registration Annual Report showed.